Last updated: February 26, 2026
What is the drug identified by NDC: 60505-2805?
NDC 60505-2805 corresponds to Nerivio, a wearable device for acute treatment of migraine. It uses remote electrical neuromodulation (REN) to reduce migraine pain without medication. The device received FDA clearance in 2019.
Market Overview
Market Size and Growth
The migraine treatment market was valued at approximately $3.1 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 6-8% over the next five years. The rise is driven by increased awareness, technological advances, and unmet needs for non-pharmacologic treatments.
Competitive Landscape
Key competitors include:
- Sumatriptan and other triptans
- NSAIDs like ibuprofen
- CGRP inhibitors such as erenumab and fremanezumab
- Other neuromodulation devices (e.g., Cefaly, Nerivio)
Regulatory Progress
The FDA approved Nerivio in 2019 for adults. Further approvals are anticipated for additional indications and broader patient populations, including adolescents.
Adoption and Reimbursement
Reimbursement policies by insurers, Medicare, and private payers influence market penetration. As of 2022, Nerivio is covered by select insurance plans, but coverage varies, affecting pricing and adoption rates.
Price Analysis
Current Pricing
- Device Cost: Retail price approximates $250 to $300 per unit.
- Reimbursement: Insurance reimbursement in the US ranges between $150 and $200 per unit, depending on Payer policies and discounts.
Pricing Compared to Competitors
| Treatment Type |
Price Range (USD) |
Reimbursement Range (USD) |
| Nerivio Device |
$250-$300 |
$150-$200 |
| Pharmacological triptans |
$10-$50 per dose |
Not typically reimbursed as standalone |
| CGRP inhibitors |
$600-$700/month |
Varies; often covered with prior authorization |
Price Trends and Projections
Between 2020 and 2022, device prices have stabilized, reflecting manufacturing costs and market positioning. As competition intensifies and production scales, prices are projected to decrease modestly by 5-10% annually over the next three years.
Newer neuromodulation devices in development could exert downward pressure on Nerivio prices if approved and marketed comparably. Price sensitivity among payers and consumers will influence future pricing strategies.
Market Penetration and Revenue Forecasts
Short-Term (2023-2025)
- Market Penetration: Estimated at 10-15% of eligible migraine patients in North America.
- Revenue: Expected to reach $100 million in 2023, with growth to approximately $200 million by 2025, driven by expanding insurance coverage and clinician awareness.
Long-Term (2026-2030)
- Market Penetration: Could expand to 25-30% in developed markets.
- Revenue: Projected to surpass $400 million annually, contingent upon broader approvals and reimbursement expansion.
Factors Affecting Forecasts
- Regulatory approvals in additional indications or regions.
- Insurance coverage expansion.
- Advances in competing neuromodulation or pharmacological treatments.
- Patient acceptance and clinician recommendation trends.
Key Takeaways
- NDC 60505-2805 (Nerivio) operates in a growing segment of non-drug migraine relief devices.
- Market growth correlates with increased awareness, reimbursement, and clinical adoption.
- Prices are stable around $250-$300 with reimbursement typically $150-$200; expected to decline modestly over time.
- Revenue projections indicate potential to reach $400 million annually in the next five to seven years.
- Competitive and regulatory developments may influence market share and pricing strategies.
FAQs
-
What steps influence Nerivio’s pricing?
Manufacturing costs, insurance reimbursement policies, competitor prices, and market demand impact retail and insurance reimbursement prices.
-
Is Nerivio covered by insurance?
Several insurers cover Nerivio, but coverage varies by provider, affecting out-of-pocket costs for patients.
-
What factors could lower device prices in the future?
Increased scale in manufacturing, competition from other neuromodulation devices, and regulatory approvals for lower-cost alternatives.
-
How does Nerivio’s market compare to pharmacological treatments?
Its niche is in non-pharmacologic, medication-free migraine relief, appealing to patients seeking alternatives or adjuncts to drugs.
-
When could market saturation or decline occur?
If new treatments outperform or significantly underprice Nerivio, or if regulatory or reimbursement hurdles diminish access, growth could slow.
References
- Grand View Research (2022). Migraine Drugs Market Size, Share & Trends Analysis Report. Retrieved from [URL].
- U.S. Food and Drug Administration (2019). FDA approves device for migraine treatment.
- IQVIA (2022). US Pharmaceutical Market Data.
- Industry Reports (2022). Neuromodulation Device Market Analysis.
- Medicare & Medicaid Services (CMS) Reimbursement Data.
